Life Science REIT (DB:JL6) - Cotización, noticias y análisis

Resumen de acción JL6

Sin descripción comercial

JL6 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	0/6
Financial Health	2/6
Dividends	2/6

Recompensas

Análisis de riesgos

El dividendo de 5.18% no está bien cubierto por beneficios o flujos de caja

Tiene menos de 1 año de cash runway

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Life Science REIT plc

Deutsche Konsum REIT-AG

XTRA:DKG

€94.2m

Fair Value REIT-AG

DB:FVI

€55.8m

Hamborner REIT

XTRA:HABA

€555.6m

alstria office REIT-AG

XTRA:AOX

€616.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Life Science REIT
Historical stock prices
Current Share Price	UK£0.41
52 Week High	UK£0.86
52 Week Low	UK£0.39
Beta	0.13
1 Month Change	-14.52%
3 Month Change	-38.51%
1 Year Change	-42.78%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-60.32%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	JL6	DE Health Care REITs	Mercado DE
7D	-5.1%	0%	0%
1Y	-42.8%	0%	0%

Volatilidad de los precios

Is JL6's price volatile compared to industry and market?
JL6 volatility
JL6 Average Weekly Movement	7.5%
Health Care REITs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in DE Market	0%
10% least volatile stocks in DE Market	0%

Precio estable de las acciones: El precio de las acciones de JL6 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de JL6(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	n/a	Simon Farnsworth	www.lifesciencereit.co.uk

Resumen de fundamentos de Life Science REIT plc

¿Cómo se comparan los beneficios e ingresos de Life Science REIT con su capitalización de mercado?
Estadísticas fundamentales de JL6
Capitalización bursátil	€157.34m
Beneficios(TTM)	-€25.28m
Ingresos (TTM)	€23.23m

6.8x

Ratio precio-ventas (PS)

-6.2x

Ratio precio-beneficio (PE)

¿Está JL6 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de JL6
Ingresos	UK£19.94m
Coste de los ingresos	UK£6.12m
Beneficio bruto	UK£13.83m
Otros gastos	UK£35.53m
Beneficios	-UK£21.71m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.062
Margen bruto	69.33%
Margen de beneficio neto	-108.85%
Ratio deuda/patrimonio	38.0%

¿Cómo se ha desempeñado JL6 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

5.2%

Rentabilidad actual por dividendo

184%

Ratio de pagos

Resumen de acción JL6

Recompensas

Análisis de riesgos

Competidores de Life Science REIT plc

XTRA:DKG

€94.2m

DB:FVI

€55.8m

XTRA:HABA

€555.6m

XTRA:AOX

€616.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New minor risk - Share price stability

New minor risk - Financial position

Full year 2023 earnings released: UK£0.062 loss per share (vs UK£0.079 loss in FY 2022)

Life Science REIT plc, Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

Life Science REIT plc to Report Fiscal Year 2023 Results on Mar 26, 2024

Recent updates

New minor risk - Share price stability

New minor risk - Financial position

Full year 2023 earnings released: UK£0.062 loss per share (vs UK£0.079 loss in FY 2022)

Life Science REIT plc, Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

Life Science REIT plc to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released

Life Science REIT plc Declares an Interim Dividend for the Six Months Ended 30 June 2023, Payable on 31 October 2023

Life Science REIT plc to Report Q2, 2023 Results on Sep 21, 2023

Upcoming dividend of UK£0.03 per share at 6.6% yield

Full year 2022 earnings released: UK£0.079 loss per share (vs UK£0.053 profit in FY 2021)

Life Science REIT plc Declares First Interim Dividend, Payable on 31 October 2022

Life Science REIT plc Approves Election of Directors

Life Science Reit plc Announces Change of Role of Richard Howell from Non-Executive Director to Senior Independent Director and Appointment as Chair of the Audit and Risk Committee

Life Science Reit PLC to Report First Half, 2022 Results on Sep 22, 2022

Life Science Reit PLC (AIM:LABS) acquired Oxford Technology Park from Angus and Alicia Bates for £120.3 Million.

Life Science Reit PLC (AIM:LABS) acquired 7-11 Herbrand Street from LabTech Investments Ltd for £85 million.

Life Science Reit PLC Announces Executive Changes

Life Science Reit PLC (AIM:LABS) acquired three freehold buildings at Cambourne Business Park near Cambridge from Coal Pension Properties Limited for £50.1 million.

Life Science Reit PLC (AIM:LABS) acquired Three buildings at the Cambourne Business Park near Cambridge for £38.7 million.

Life Science Reit PLC (AIM:LABS) acquired The Merrifield Centre in Cambridge for £4.8 million.

Life Science Reit PLC (AIM:LABS) acquired Rolling Stock Yard from Newmark Property Investments Ltd., Investec Bank Limited (JSE:INLP) and Argo Real Estate Management Limited for £77 million.